News Search Results
Sep 14, 2026, 10:31 ET Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis,
More news about: DelveInsight Business Research, LLP
Aug 14, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings, showed an 86% objective response rate, including 57% complete response,
More news about: Citius Pharmaceuticals, Inc.
Aug 14, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
and,Phase 1 data for LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presented at 2026 ASTCT® & CIBMTR® Tandem Meetings, demonstrating:86% ORR, including 57% complete response
More news about: Citius Oncology, Inc.
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
glofitamab. As the Company continues to commercialize ZYNLONTA in the 3L+ DLBCL setting, we will work closely with the FDA to determine how to best obtain full approval and to advance ZYNLONTA combinations into earlier lines of therapy in DLBCL."We are pleased by our second quarter performance, which reflects
More news about: ADC Therapeutics SA
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. Monjuvi is not indicated and is not recommended for
More news about: Specialised Therapeutics
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of Epkinly (epcoritamab) and lenalidomide, compared to rituximab plus gemcitabine plus oxaliplatin in adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy.
More news about: AbbVie
Jul 22, 2026, 10:31 ET CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight
CTX110, bbT369, and others.In 2036, among all the therapies for CAR T- cell in NHL, the highest revenue is estimated to be generated by DLBCL in the United States.Discover what is the future of the CAR T-cell therapy for NHL treatment market @
More news about: DelveInsight Business Research, LLP
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
data available on patients with CD20-negative DLBCL and patients with CD20-negative FL treated with Tepkinly, and it is possible that patients with CD20-negative DLBCL and CD20-negative FL may have less benefit compared to patients with CD20-positive DLBCL and patients with CD20-positive FL, respectively.
More news about: AbbVie
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
data available on patients with CD20-negative DLBCL and patients with CD20-negative FL treated with Tepkinly, and it is possible that patients with CD20-negative DLBCL and CD20-negative FL may have less benefit compared to patients with CD20-positive DLBCL and patients with CD20-positive FL, respectively.
More news about: AbbVie
Jun 30, 2026, 07:15 ET ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated
More news about: ADC Therapeutics SA
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated
More news about: AbbVie
Jun 25, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although ADC's treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared to the nine
More news about: Pomerantz LLP
Jun 24, 2026, 07:30 ET ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated
More news about: ADC Therapeutics SA
Jun 18, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although ADC's treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared to the nine
More news about: Pomerantz LLP
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although ADC's treatment extended progression-free survival by 1.4 months, 27 deaths were recorded for those given Zynlonta, compared to the nine
More news about: Pomerantz LLP
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentations,
More news about: AbbVie
Jun 08, 2026, 08:00 ET AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentations,
More news about: AbbVie
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
malignancies, including DLBCL, CLL/SLL and Marginal zone lymphoma (MZL). The guidelines also include a note indicating rocbrutinib's efficacy as monotherapy or in combination therapy for patients with R/R DLBCL.Based on preliminary study results in adult patients with non-GCB DLBCL who had received at
More news about: Lupeng Pharmaceutical Ltd
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated
More news about: ADC Therapeutics SA
May 28, 2026, 12:30 ET Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
lymphoblastic markers including full coverage of BTK to help genomically characterize lymphoid malignancies including CLL/SLL, WM/LPL, FL, MCL, DLBCL/LBCL, HCL, and multiple T-cell entities.These oncoReveal panels are currently available to customers worldwide.Expanding access
More news about: Illumina, Inc.
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
Fixed-duration subcutaneous (SC) mosunetuzumab (Mosun) in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Interim analysis and patient-reported outcomes (PROs) from the phase 2 MorningSun study
More news about: Florida Cancer Specialists & Research Institute
May 26, 2026, 04:50 ET Du Pakistan à Shanghai : un parcours CAR-T dans la lutte contre le lymphome récidivant
sang récurrent agressif. Muhammad, membre du personnel hospitalier de Quetta, au Pakistan, souffrait d'un lymphome diffus à grandes cellules B (DLBCL). Après plusieurs chimiothérapies et l'échec d'une greffe de moelle osseuse, sa maladie a progressé au stade IVB (métastase) au début de 2026, avec
More news about: Jiahui Health
May 26, 2026, 04:31 ET Von Pakistan nach Shanghai: Eine CAR-T-Behandlung im Kampf gegen ein rezidiviertes Lymphom
Blutkrebserkrankung durchlaufen hatte. Muhammad, ein Krankenhausmitarbeiter aus Quetta, Pakistan, litt an einem diffusen großzelligen B-Zell-Lymphom (DLBCL). Nach mehreren Chemotherapiezyklen und einer fehlgeschlagenen Knochenmarktransplantation schritt seine Erkrankung bis Anfang 2026 bis zum Stadium IVB
More news about: Jiahui Health
May 24, 2026, 20:47 ET From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma
for aggressive recurrent blood cancer. Muhammad, a hospital staff member from Quetta, Pakistan, suffered from diffuse large B-cell lymphoma (DLBCL). After multiple chemotherapy courses and a failed bone marrow transplant, his disease progressed to Stage IVB by early 2026, with widespread metastasis
More news about: Jiahui Health